SOURCE-LINKED INTELLIGENCE

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

TechCrunch AI · article · Sep 23, 2026 · UTC

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

Read original source ↗ Open in workspace

recordType: article
region: Global

Evidence & attribution

TechCrunch AI · 2026-09-23T19:31:28.000Z

First collected: 2026-09-23T23:42:23.408Z. This is not the publication date.